Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.58 |
| ▸ | HTR7 | P34969 | 4/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.58 |
| ▸ | HTR3B | O95264 | 3/20 | 0.58 |
| ▸ | HTR3A | P46098 | 3/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4713477 | 0.98 | ADRB1 (0.57) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Trifluoroacetic Acid SCHEMBL2326391 | 0.90 | ALDH1A1 (0.52) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL117252 | 0.85 | ALDH1A1 (0.73) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL30966888 | 0.85 | ALDH1A1 (0.73) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL3868910 | 0.85 | ADRB1 (0.60) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL31107600 | 0.85 | ADRB1 (0.60) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL11738763 | 0.85 | ALDH1A1 (0.72) | TP53HTTALDH1A1HSD17B10USP2 | |
| SCHEMBL15579368 | 0.84 | ADRB1 (0.58) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL3072477 | 0.84 | ADRB1 (0.58) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL6503848 | 0.84 | ADRB1 (0.58) | ADRB1HTR7HTR1AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| US-20110155660-A1 | MODIFIED MEMBRANE | DOW GLOBAL TECHNOLOGIES LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110155660-A1 | MODIFIED MEMBRANE | DOW GLOBAL TECHNOLOGIES LLC | 2011-06-30 | — | — | US | disclosed |
| US-7882963-B2 | modifying polyamide discriminating layer ( e.g metaphenylene diamine- trimesoyl chloride monomers) with aminoacetophenone or aminothiophenol; fouling resistant surface, improved salt rejection, antimicrobial properties, improved solute, and/or small organics rejection; for water purification | DOW GLOBAL TECHNOLOGIES INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7882963-B2 | modifying polyamide discriminating layer ( e.g metaphenylene diamine- trimesoyl chloride monomers) with aminoacetophenone or aminothiophenol; fouling resistant surface, improved salt rejection, antimicrobial properties, improved solute, and/or small organics rejection; for water purification | DOW GLOBAL TECHNOLOGIES INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1428822-B1 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090159527-A1 | MODIFIED MEMBRANE | DOW GLOBAL TECHNOLOGIES LLC | 2009-06-25 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | disclosed |
| EP-1240142-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-5780472-A | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAZL CO., LTD. (KR) | 1998-07-14 | — | — | US | disclosed |
| WO-1998002432-A1 | BICYCLIC COMPOUNDS FOR CONTROLLING MICTURITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | ADRB1 142/4885HTR7 233/4885HTR1A 90/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADRB1 34/4885HTR7 24/4885HTR1A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.